1
|
Putri GN, Gudla CS, Singh M, Ng CH, Idris FFH, Oo Y, Tan JHY, Wong JFJ, Chu JJH, Selvam V, Selvaraj SS, Shandil RK, Narayanan S, Alonso S. Expanding the anti-flaviviral arsenal: Discovery of a baicalein-derived Compound with potent activity against DENV and ZIKV. Antiviral Res 2023; 220:105739. [PMID: 37944824 DOI: 10.1016/j.antiviral.2023.105739] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2023] [Revised: 10/22/2023] [Accepted: 10/26/2023] [Indexed: 11/12/2023]
Abstract
With approximately 3.8 billion people at risk of infection in tropical and sub-tropical regions, Dengue ranks among the top ten threats worldwide. Despite the potential for severe disease manifestation and the economic burden it places on endemic countries, there is a lack of approved antiviral agents to effectively treat the infection. Flavonoids, including baicalein, have garnered attention for their antimicrobial properties. In this study, we took a rational and iterative approach to develop a series of baicalein derivatives with improved antiviral activity against Dengue virus (DENV). Compound 11064 emerged as a promising lead candidate, exhibiting antiviral activity against the four DENV serotypes and representative strains of Zika virus (ZIKV) in vitro, with attractive selectivity indices. Mechanistic studies revealed that Compound 11064 did not prevent DENV attachment at the cell surface, nor viral RNA synthesis and viral protein translation. Instead, the drug was found to impair the post-receptor binding entry steps (endocytosis and/or uncoating), as well as the late stage of DENV infection cycle, including virus assembly/maturation and/or exocytosis. The inability to raise DENV resistant mutants, combined with significant antiviral activity against an unrelated RNA virus (Enterovirus-A71) suggested that Compound 11064 targets the host rather than a viral protein, further supporting its broad-spectrum antiviral potential. Overall, Compound 11064 represents a promising antiviral candidate for the treatment of Dengue and Zika.
Collapse
Affiliation(s)
- Geraldine Nadya Putri
- Infectious Diseases Translational Research Programme, Department of Microbiology and Immunology, Yong Loo Lin School, National University of Singapore, Singapore; Immunology Programme, Life Sciences Institute, National University of Singapore, Singapore
| | | | - Mayas Singh
- Foundation for Neglected Disease Research, Bangalore, Karnataka, India
| | - Chin Huan Ng
- Infectious Diseases Translational Research Programme, Department of Microbiology and Immunology, Yong Loo Lin School, National University of Singapore, Singapore; Immunology Programme, Life Sciences Institute, National University of Singapore, Singapore
| | - Fakhriedzwan Fitri Haji Idris
- Infectious Diseases Translational Research Programme, Department of Microbiology and Immunology, Yong Loo Lin School, National University of Singapore, Singapore; Immunology Programme, Life Sciences Institute, National University of Singapore, Singapore
| | - Yukei Oo
- Infectious Diseases Translational Research Programme, Department of Microbiology and Immunology, Yong Loo Lin School, National University of Singapore, Singapore; Immunology Programme, Life Sciences Institute, National University of Singapore, Singapore
| | - Jasmine Hwee Yee Tan
- Infectious Diseases Translational Research Programme, Department of Microbiology and Immunology, Yong Loo Lin School, National University of Singapore, Singapore; Immunology Programme, Life Sciences Institute, National University of Singapore, Singapore
| | - Joel Feng Jie Wong
- Infectious Diseases Translational Research Programme, Department of Microbiology and Immunology, Yong Loo Lin School, National University of Singapore, Singapore; Immunology Programme, Life Sciences Institute, National University of Singapore, Singapore
| | - Justin Jang Hann Chu
- Infectious Diseases Translational Research Programme, Department of Microbiology and Immunology, Yong Loo Lin School, National University of Singapore, Singapore
| | - Vignesh Selvam
- Foundation for Neglected Disease Research, Bangalore, Karnataka, India
| | | | | | | | - Sylvie Alonso
- Infectious Diseases Translational Research Programme, Department of Microbiology and Immunology, Yong Loo Lin School, National University of Singapore, Singapore; Immunology Programme, Life Sciences Institute, National University of Singapore, Singapore.
| |
Collapse
|
2
|
Gudla CS, Selvam V, Selvaraj SS, Tripathi R, Joshi P, Shaham SH, Singh M, Shandil RK, Habib S, Narayanan S. Novel Baicalein-Derived Inhibitors of Plasmodium falciparum. Pathogens 2023; 12:1242. [PMID: 37887758 PMCID: PMC10610289 DOI: 10.3390/pathogens12101242] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2023] [Revised: 10/05/2023] [Accepted: 10/10/2023] [Indexed: 10/28/2023] Open
Abstract
Malaria, a life-threatening mosquito-borne disease caused by Plasmodium parasites, continues to pose a significant global health burden. Despite notable progress in combating the disease in recent years, malaria remains prevalent in many regions, particularly in Southeast Asia and most of sub-Saharan Africa, where it claims hundreds of thousands of lives annually. Flavonoids, such as the baicalein class of compounds, are known to have antimalarial properties. In this study, we rationally designed and synthesized a series of baicalein derivatives and identified a lead compound, FNDR-10132, that displayed potent in vitro antimalarial activity against Plasmodium falciparum (P. falciparum), both chloroquine-sensitive (60 nM) and chloroquine-resistant (177 nM) parasites. FNDR-10132 was evaluated for its antimalarial activity in vivo against the chloroquine-resistant strain Plasmodium yoelii N67 in Swiss mice. The oral administration of 100 mg/kg of FNDR-10132 showed 44% parasite suppression on day 4, with a mean survival time of 13.5 ± 2.3 days vs. 8.4 ± 2.3 days of control. Also, FNDR-10132 displayed equivalent activity against the resistant strains of P. falciparum in the 200-300 nM range. This study offers a novel series of antimalarial compounds that could be developed into potent drugs against chloroquine-resistant malarial parasites through further chemistry and DMPK optimization.
Collapse
Affiliation(s)
| | - Vignesh Selvam
- Foundation for Neglected Disease Research, Bangalore 561203, Karnataka, India
| | | | - Renu Tripathi
- Molecular Microbiology and Immunology, CSIR—Central Drug Research Institute, Lucknow 226301, Uttar Pradesh, India
| | - Prince Joshi
- Molecular Microbiology and Immunology, CSIR—Central Drug Research Institute, Lucknow 226301, Uttar Pradesh, India
| | - Salique Hassan Shaham
- Molecular Microbiology and Immunology, CSIR—Central Drug Research Institute, Lucknow 226301, Uttar Pradesh, India
| | - Mayas Singh
- Foundation for Neglected Disease Research, Bangalore 561203, Karnataka, India
| | | | - Saman Habib
- Biochemistry and Structural Biology, CSIR—Central Drug Research Institute, Lucknow 226301, Uttar Pradesh, India
| | - Shridhar Narayanan
- Foundation for Neglected Disease Research, Bangalore 561203, Karnataka, India
| |
Collapse
|